Four vaginal energy devices tied on symptoms — with no sham arm to beat

Energy-based devices — vaginal lasers and radiofrequency systems — are widely marketed for genitourinary syndrome of menopause, the cluster of dryness, painful intercourse, and urinary symptoms that follows the loss of oestrogen. A four-arm randomised trial published in Maturitas on September 25 compared four of them against each other, and found no difference [s1].

The result is worth reading carefully, because what the trial compared determines what the result can mean.

What the trial did

Forty-eight postmenopausal women with genitourinary syndrome of menopause were randomised into four groups in a single-blind trial registered with the Brazilian Registry of Clinical Trials (RBR-5vw3vpg) [s1]. Group 1 received non-ablative Er:YAG laser, Group 2 microablative CO2 laser, Group 3 non-ablative radiofrequency, and Group 4 fractional microablative radiofrequency [s1].

The primary outcome combined symptom assessment with vaginal histological analysis at baseline and one month after treatment ended [s1]. Secondary outcomes were sexual function, urinary symptoms, treatment satisfaction, and major adverse events [s1].

Including histology is unusual and useful. Symptom scales in this condition move a great deal with attention and expectation; tissue does not.

The findings

All four modalities produced significant improvement in dryness (p < 0.001) and dyspareunia (p < 0.001) on visual analogue scales, and in vaginal symptoms measured by the International Consultation on Incontinence Questionnaire–Vaginal Symptoms (p < 0.001), with no significant differences between groups [s1].

All four also produced significant increases in tissue thickness (p < 0.001), number of epithelial layers (p < 0.001), and collagen quantity and depth (p < 0.001), again with no significant difference between the groups [s1].

The authors conclude that microablative and non-ablative energies, whether laser or radiofrequency, are effective for symptoms of genitourinary syndrome of menopause, with histological correlation and no notable efficacy difference between modalities [s1].

The comparison that is missing

There is no sham arm and no untreated control [s1]. Every participant received an active device. "All four improved and none beat the others" is therefore compatible with two very different underlying facts: that all four work about equally well, or that none of them does anything specific and all four groups improved for the reasons untreated groups improve — regression to the mean, repeated clinical attention, the lubricating effect of the procedure itself, and the well-documented placebo response in genitourinary symptom scales.

That is not a hypothetical concern here. The only large double-blind sham-controlled trial of a vaginal laser found no benefit. In 85 postmenopausal women randomised at a tertiary referral hospital in Sydney to three fractional CO2 laser treatments or three sham treatments, with 78 (91.7%) completing 12-month follow-up, there was no significant difference between groups in symptom severity on a visual analogue scale (change −17.2 with laser vs −26.6 with sham; difference 9.4, 95% CI −28.6 to 47.5) or on the Vulvovaginal Symptom Questionnaire (−3.1 vs −1.6; difference −1.5, 95% CI −5.9 to 3.0) [s2].

Notably, that trial also found no difference in histological comparisons between laser and sham groups [s2] — which complicates the inference that tissue change in the new trial demonstrates a device-specific effect.

The sham group in the Sydney trial improved substantially on its own. That is the number that makes an uncontrolled four-arm comparison hard to interpret.

Other limits

Forty-eight women split four ways gives twelve per arm [s1]. A trial that size can only detect very large differences between modalities; the finding of "no significant difference between groups" is close to guaranteed by the sample size regardless of the truth.

Follow-up was one month after the end of treatment [s1]. The Sydney trial's primary endpoint was at 12 months [s2]. Genitourinary syndrome of menopause is a chronic condition driven by ongoing oestrogen deficiency, and short-term symptom change is a weak guide to durable benefit.

The trial was single-blind, meaning participants were not blinded to which device they received [s1].

Why this keeps mattering

Energy-based vaginal treatments are typically paid for out of pocket and delivered in courses of several sessions. The evidence question — do they outperform sham — is therefore also a consumer protection question. A trial comparing four active devices at twelve patients per arm cannot answer it, however carefully conducted.

What the new trial does contribute is a genuine head-to-head signal: nothing in the data suggests one energy modality outperforms another, and non-ablative approaches performed no worse than microablative ones [s1]. If a device effect exists, this trial gives no reason to prefer the more aggressive version of it.

What to watch

Whether adequately powered sham-controlled trials with 12-month endpoints are conducted for radiofrequency, which has less sham-controlled evidence than laser; whether histological change without symptom separation from sham is replicated; and how professional societies weigh this literature in guidance on non-hormonal options.

This article describes randomised trial results and is informational only. It is not medical advice and does not recommend any device or procedure.